Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort

Sarah Averill Lott[1], Emmanuel Streel[2], Shelby L. Bachman[3], Kai Bode[4], John Dyer[5], Cheryl Fitzer-Attas[6], Jennifer C. Goldsack[1], Ann Hake[7], Ali Jannati[8], Ricardo Sainz Fuertes,[9] Piper Fromy[1]

1. Digital Medicine Society (DiMe), Boston, MA, USA

2. Altoida, Washington DC, USA

3. VivoSense, Inc., Newport Coast, CA, USA

4. Merck, Rahway, PA, USA

5. Cumulus Neuroscience, Belfast, UK

6. Cogniant Pte Ltd, Singapore and ClinMed LLC, Dayton, NJ, USA

7. Eli Lilly and Company, Indianapolis, IN, USA

8. Linus Health, Inc., Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA

9. Global Alzheimer's Disease Office, Eisai, Spain

* Corresponding author: Sarah Averill Lott, sarah.lott@dimesociety.org, 970-408-0780

Abstract

Digital health technologies offer valuable advantages to dementia researchers and clinicians as screening tools, diagnostic aids, and monitoring instruments. To support the use and advancement of these resources, a comprehensive overview of the current technological landscape is essential.

A multi-stakeholder working group, convened by the Digital Medicine Society (DiMe), conducted a landscape review to identify digital health technologies for Alzheimer's disease and related dementia populations. We searched studies indexed in PubMed, Embase, and APA PsycInfo to identify manuscripts published between May 2003 to May 2023 reporting analytical validation, clinical validation, or usability/feasibility results for relevant digital health technologies. Additional technologies were identified through community outreach. We collated peer-reviewed manuscripts, poster presentations, or regulatory documents for 106 different technologies for Alzheimer's disease and related dementia assessment covering diverse populations such as Lewy Body, vascular dementias, frontotemporal dementias, and all severities of Alzheimer's disease. Wearable sensors represent 32% of included technologies, non-wearables 61%, and technologies with components of both account for the remaining 7%. Neurocognition is the most prevalent concept of interest, followed by physical activity and sleep. Clinical validation is reported in 69% of evidence, analytical validation in 34%, and usability/feasibility in 20% (not mutually exclusive).

These findings provide clinicians and researchers a landscape overview describing the range of technologies for assessing Alzheimer's disease and related dementias. A living library of technologies is presented for the clinical and research communities which will keep findings up-to-date as the field develops.

Keywords: digital health technologies, Alzheimer's disease, assessment, digital medicine

DHTs for Alzheimer's disease and related

Introduction

The uses for digital health technologies (DHTs) for clinical research, personalized medicine, and general wellness are well established and continue to expand [1, 2]. In the field of Alzheimer's disease and related dementias (ADRD), growth in the development and use of DHTs [3] is occurring alongside increased research and development of drugs for the prevention and treatment of Alzheimer's disease (AD) and other dementia-inducing disorders including Lewy Body and frontotemporal dementias[4–6]. The recent regulatory approval of some therapeutic agents targeting AD pathophysiology highlights the complexity of dementia management, as new treatment opportunities emerge alongside ongoing challenges in dementia research, clinical management, and holistic patient care [7]. These challenges include identifying digital biomarkers that signal changes early in the disease course when intervention is more likely to provide a substantial impact; assessing clinical manifestations of dementia such as activities of daily living (ADLs), cognitive function, physical activity, and sleep; evaluating and demonstrating response to therapeutic interventions [8]; and improving recruitment (including recruitment of diverse patient groups [9], retention, and assessment of participants in clinical trials). In addressing these challenges, clinicians and researchers will benefit from utilizing DHTs as fit for purpose tools that can play a strategic role in screening, monitoring, and longitudinal assessment in research, clinical, and real world settings.

Members of a global, multi-stakeholder working group convened by the Digital Medicine Society (DiMe)[10] met over several months to assess the characteristics of DHTs in ADRD populations, recognizing the immense opportunity for further research

DHTs for Alzheimer's disease and related

and clinical impact alongside the ever-increasing burden of Alzheimer's disease and related dementias[11, 12]. DiMe, a global non-profit dedicated to driving scientific progress and broad acceptance in digital medicine to redefine healthcare and improve lives, hosts the Digital Health Measurement Collaborative Community (DATAcc)[13], a U.S. Food and Drug Administration (FDA) Center for Diagnostic and Radiological Health (CDRH) collaborative community[14], and convenes a wide range of stakeholders and subject matter experts in pre-competitive forums to advance the field.

While others have examined the evidence for ADRD-relevant DHTs[15, 16], such efforts are often limited to a subset of available technologies or therapeutic domains, obscuring substantial portions of the DHT landscape and restricting opportunities for translation of the benefits of these tools across different dementias. To obtain a more comprehensive view, our ADRD working group aggregated multiple technologies across ADRD-therapeutic areas by surveying 20 years of peer-reviewed literature and then sourcing additional evidence from DHT users and developers. While we were primarily informed by the literature and had strict inclusion and exclusion criteria, our purpose in this exercise was to identify and collect digital health technologies in use for dementia measurement, not to interrogate the literature for quality or bias as one would expect in a traditional systematic literature review. Rather, our broad landscape assessment was literature-based and community supported, as the DiMe working group (comprised of ADRD experts from clinical, pharmaceutical, industry research and development, and patient advocacy domains; see acknowledgments for complete list of participating organizations) were given an opportunity to review the findings and identify additional technologies for consideration.

DHTs for Alzheimer's disease and related

The results of this innovative effort are reported here, bringing an open science perspective and outlining the state of digital innovation in ADRD research. As a precompetitive group representing a range of interests, we do not promote any specific technology type, product, or developer in this analysis and therefore refrain from providing direct product examples in-text; a list of all sources that inform this overview is provided in the supplement so that interested readers may seek specific examples if desired. Here we provide a general overview advancing awareness of the range of technologies and their uses for dementia assessment.

Methods

Data Sources:

The working group sought to identify DHTs with associated evidence of validity[17] and therefore started by turning to the peer-reviewed literature. In May 2023, we conducted a landscape review to identify DHTs being used for assessment in ADRD populations by the clinical and research communities. The search strings (*see supplementary material*) included terminology to identify DHTs, diagnostic and descriptive terms to focus on ADRD-relevant populations, and pertinent concepts of interest measured by a DHT including sleep health, memory, language, social function, oculomotor function, cognition, life space mobility, essential bodily functioning, and emotional or behavioral concerns. The selection of these concepts of interest was informed by literature focused on meaningful aspects of health[8, 18, 19] for ADRD stakeholders at large. We restricted search results to primary research studies with human participants published within the last 20 years. To avoid over-representation of any given technology brand, we intentionally did not include any name-brand affiliated keywords in the search terms, knowing this might mean relevant studies were omitted from the results if they included only brand identifiers for utilized technologies. The search string was performed within PubMed, APA PsycInfo, and Embase literature databases, and the results were then aggregated and deduplicated within reference management software Zotero[20].

Literature Review Screening

DHTs for Alzheimer's disease and related

Identified articles were screened by two reviewers (SAL, PF), with a random sample of 5% co-reviewed to ensure harmony on inclusion/exclusion standards. Articles were included or excluded based on the criteria outlined in Table 1.

Literature Screening Criteria	
Population	Exclude studies that do not capture data from human participants
	Include studies that reference a DHT used for assessment or diagnosis in Alzheimer's or related dementia populations
	Exclude studies limited to Parkinson's disease populations
Concept of interest	Include studies where a DHT focused on sleep health, memory, language, social function, oculomotor function, cognition, life space mobility, essential bodily functioning, and emotional or behavioral concerns
Application	Exclude studies where the featured DHT was: • being explicitly evaluated as a digital therapeutic or as an intervention • dependent on in-hospital or in-clinic administration and unlikely to be accessible in a real world setting, e.g., magnetic resonance or computed tomography imaging • an algorithm exclusively trained for and on aggregated imaging or electronic health record data. We did include any algorithms trained on data capable of being collected outside a laboratory setting through remote digital sensor technology
Evidence characteristics	Include studies with data reporting at least one of the following categories: • verification • analytical validation • clinical validation • use in clinical trial settings • usability or feasibility.
Time frame	Include studies published in the last 20 years

Table 1. Inclusion/exclusion criteria applied to papers identified in literature search or returned by survey

DHTs for Alzheimer's disease and related

Extraction

From each qualifying manuscript, we extracted the name and manufacturer of the technology being utilized; the technology type, form factor, and wear location; the reported therapeutic category and population descriptors as described verbatim by study authors; and the general health concepts and outcomes under assessment. Categories used elsewhere in assessing and categorizing DHTs informed our classification labels[21, 22] for technology types and health outcomes. Technology types were sorted into ambient (standalone, not worn on the body), wearable (worn on the body for any period of time), implantable (surgically placed), or ingestible (swallowed); while form factor descriptions were as provided by study authors in the text. Broad health outcome categories were sorted into activities of daily living, mental health, neurocognitive, neurological or sensory, physical activity, and sleep. More specific health outcome category labels were derived from study descriptors and are also reported. Lastly, we labeled evidence according to the type of data it reported: verification, analytical validation, clinical validation, and usability or feasibility[17]. When extracting these evidence types and other characteristics such as diagnostic classifications, study populations descriptors, or outcome measures, we adhered to author/publication verbiage as closely as possible with the goal of collating rather than interpreting labels or assessing individual pieces of evidence as to their rigor or performance.

Community Sourcing:

ADRD subject matter experts in DHT development, clinical trials, and clinical care from the DiMe ADRD project team[10] reviewed and added to the list of technologies created during extraction, to identify additional technologies not captured in our

literature search. Developers of identified DHTs were contacted by email (when contact information was accessible) and provided a survey via a Qualtrics[23] link where they could return peer reviewed articles, conference posters or presentations, regulatory documents, datasets, open-source algorithms, or other supporting materials for their technologies in line with the V3 framework [17]. If a developer responded and provided any evidence, that data was assessed against the same inclusion and exclusion standards for the literature presented in Table 1 and included in our results if eligible. Finally, the survey link and a description of the library were shared on LinkedIn during World Alzheimer's Month in an effort to solicit evidence for ADRD DHTs from the broader scientific and digital health communities (September, 2023).

Results

The combined literature search resulted in an initial dataset of 1,743 manuscripts; after screening we identified 153 eligible articles related to 117 unique DHTs. We reviewed and omitted 13 technologies that were clearly obsolete and discontinued, bringing the results from the literature to 102 DHTs. Project partners reviewed the complete list and made us aware of an additional 57 technologies, resulting in a potential total of 159 unique DHTs for ADRD assessment. Surveys were disseminated via email to technology developers of the additional technologies to request evidence so their technologies could be considered for inclusion; as of this writing, 42 survey submissions featuring 17 technologies were returned. Survey responses included peer-reviewed publications, conference poster and oral presentation materials, and documentation of regulatory approvals. After assessing all returned materials for eligibility as outlined in Table 1, our total results included 172 pieces of evidence representing 106 unique DHTs. A list of the results of eligible manuscripts/evidence and the respective technologies therein is available in the supplementary material.

Populations Represented

Our results captured a wide variety of ADRD population descriptors as reported by study authors or DHT developers (Table 2). The classifications most represented include Mild Cognitive Impairment (MCI) in 39% of evidence records and 49% of technologies, followed by the general classification of Alzheimer's disease indicated in 31% of evidence records and 40% of technologies.

DHTs for Alzheimer's disease and related

Population		Evidence Records (n=172)	Associated Technologies (n=106)
Dementia	Cognitive-Frailty	1	1
	Subjective Cognitive Decline	7	5
	Mild Cognitive Impairment (MCI)	67	52
	Prodromal Dementia	5	5
	Preclinical Dementia	21	16
	Mild Dementia	4	4
	Moderate Dementia	1	1
	Severe Dementia	1	1
	Dementia	55	44
	Vascular Dementia	3	3
Alzheimer's Disease	Prodromal Alzheimer's Disease	5	4
	Mild Cognitive Impairment (MCI), Alzheimer's Disease	27	21
	Mild Alzheimer's Disease	31	24
	Moderate Alzheimer's Disease	19	16
	Severe Alzheimer's Disease	9	9
	Alzheimer's Disease	53	42
Frontotemporal Dementia	Frontotemporal Dementia, behavioral variant	4	3
	Frontotemporal Dementia, primary progressive aphasia	6	4
	Frontotemporal Dementia	13	12
Lewy Body Dementia	Lewy Body Dementia	12	8
Parkinson's Disease	Prodromal Parkinson's Disease	1	1
	Parkinson's Disease	11	8

Table 2. Frequencies of population areas of focus in the library, as reported in manuscripts. Many pieces of evidence reference multiple diagnostic classifications.

Technology Types, Form Factors, and Health Concepts

DHTs for Alzheimer's disease and related

Ambient (or non-wearable sensor technologies) are the most prevalent technology type, representing 61% of included DHTs and 68% of the evidence (Table 3). This category includes environmental or stand alone sensors as well as software and application-based technologies which are not tied to a given device. 83% of ambient technologies fall into the software and application category. Wearable sensor devices represent 32% of DHTs and 26% of evidence. Seven percent of technologies incorporate both wearable and ambient technologies. The most common form factors are software and applications designed for a tablet or smartphone (42% DHTs; 45% of evidence) and sensors worn on the body but not as a smartwatch (e.g. attached via a strap or brace) (19% DHTs; 16% of evidence). Cameras and contactless sensors are also strongly represented in the ambient category (collectively 13% DHTs; 14% evidence), while smartwatches represent a smaller portion of the results (8% DHTs; 5% evidence). Most studies feature commercially available DHTs (89% of evidence) though we included experimental/noncommercial DHTs if relevant to our population and concepts of interest (11% evidence). Our results also returned examples of "smart home" applications with a combination of different technology types designed to passively monitor life space mobility such as cameras, movement detecting radar, or pressure mats.

Technology Type and Form Factor		Evidence Records (n-172)	Technologies (n=106)
Type	Ambient	117	65
	Wearables	45	34
	Combination ambient/wearable	10	7
Physical Form Factor*			
	Accessory such as ring or pendant	2	2
	Adhesive patch	6	4

DHTs for Alzheimer's disease and related

Camera	11	7
Clothing	2	2
Contactless	13	7
Floor mat or plate	3	2
Headset, helmet, or headband	8	6
Mattress pad or sheet	3	2
Microphone, handheld or fixed	7	1
Other accessory**	5	5
Ring	1	1
Smartphone or tablet	78	44
Strap or brace	27	20
Watch	9	8

* not mutually exclusive **digitized pen, wearable pendant

Table 3. Prevalent technology types and form factors represented in the ADRD DHT library. Ambient includes environmental and software or application-based technologies.

DHTs are classified into the health concepts of interest they assess, including but not limited to activities of daily living; mental health, neurocognitive function, neurological or sensory function, physical activity, and sleep (Table 4). The most frequent concept of interest is neurocognitive function with 43% of technologies and 51% of the evidence, but physical activity represents a larger portion of DHTs (48%) and is addressed in 42% of evidence. Measured outcomes as reported in included studies were analyzed to categorize the evidence into more specific health concepts. Memory is the concept of interest addressed most often as a primary focus of 26% of DHTs and 26% of evidence, but life space mobility, speech patterns and characteristics, gait and mobility, sleep, and several subdomains of memory and cognitive function are also well represented (Table 4).

DHTs for Alzheimer's disease and related

Health Concepts Being Assessed		Evidence Records (n=172)	Technologies (n=106)
Broad	Activities of daily living	11	10
	Mental health	8	6
	Neurocognitive	87	46
	Neurological or sensory	6	5
	Physical activity	72	51
	Sleep	20	16
		Evidence Records	Technologies
Specific, in order of frequency	Memory, general	45	28
	Life space mobility (physical functioning)	43	31
	Speech pattern or characteristics	36	14
	Gait	27	16
	Executive function	24	18
	Attention	17	9
	Language (production)	17	12
	Sleep duration or continuity	16	13
	Processing speed	15	10
	Working memory	15	9
	Fine motor function	14	7
	Visuospatial processing	14	9
	Energy expenditure	12	9
	Joint or head kinematics	10	9
	Gaze or visual movement	8	6
	Brain activity	6	5
	Performing activities of daily living	6	6
	Agitation	4	3
	Balance	4	3
	Sleep staging	4	4

Table 4. **Prevalent concepts of interest in the ADRD DHT library.** These are not mutually exclusive. These figures represent frequency in library evidence along with the number of corresponding technologies as of October 2023.

V3, other evidence standards in action:

The V3 framework[17] codifies best practices for evaluating verification, analytical validation, and clinical validation to determine whether DHTs are fit for purpose. Briefly, these processes evaluate whether sensor-based technologies and their algorithm(s) measure and interpret what they intend to measure, and provide metrics that are clinically or functionally meaningful in the stated context of use[17]. To reflect these standards, we categorized evidence to indicate when it reports verification, analytical validation, clinical validation, and/or usability. Most of the current evidence reports validation: 34% of the evidence reports analytical validation while a majority (69%) reports evidence for clinical validation within ADRD populations. 19% percent of the evidence reports demonstrated usability or feasibility within ADRD populations. Just three manuscripts reported verification. These categories are not mutually exclusive; a single manuscript might report on multiple aspects.

Discussion

To the best of our knowledge, this review is the first to broadly document the growing landscape of DHTs available for assessment within the ADRD space. DHTs focused on cognition and memory are unsurprisingly prevalent in our results. However, we identified several other concepts of interest in the literature, underscoring the versatility DHTs offer for holistic assessment of ADRD populations. When examining technology types, mobile or software applications are prevalent and their broad scope is notable. We find these technologies are being used by researchers and clinicians to assess multiple aspects of neurocognition (including several types of memory, attention, executive functioning, and processing speed); speech production and language characteristics; fine motor functioning; oculomotor behavior; sleep; gait, mobility, or balance; life space mobility dynamics; and emotional or other behavioral patterns. Given the ubiquity of smartphones and web-based options for assessment, these findings indicate a large capacity for sensitive and ongoing patient assessment or monitoring in clinical and real world settings, including the critical opportunity to reach patients not previously accessible to research or therapeutic settings. A majority (89%) of our results feature commercially available DHTs, emphasizing that a range of technological solutions are available and in use by clinicians and researchers even as additional development and innovation continues.

Biomarkers, early detection opportunities, and digital phenotyping
Our results indicate researchers are leveraging DHTs to identify digital biomarkers and behavioral changes that can provide early indicators of functional and cognitive changes in both clinical and remote settings. Examples include but are not limited to

DHTs for Alzheimer's disease and related

wearable headbands for in-home EEG assessment to monitor sleep, sophisticated analysis of speech patterns and vocal dynamics as captured by smartphone speakers, cameras tracking patterns in narrow applications (gaze/eye movement) as well as broad (behavioral) patterns in the home; and inertial sensors worn on the lower back, chest, arm, or leg to monitor mobility patterns. These technologies detect subtle functional and behavioral differences that can differentiate patients from healthy controls and discriminate between disease stages. When tablet or smartphone apps, wearables, and other DHTs are used in aggregate, the results can be quite illustrative, providing a "digital phenotype" [24] that captures a comprehensive in-situ portrait of someone's daily functional and cognitive status, providing a better window into a patient's emotional state, social patterns, and physical experiences to generate research insights and guide clinical care in ways that are meaningful to patients[25]. "Smart home" applications show promise in this regard as well, with personalized and multimodal monitoring that might include cameras that track life space mobility paired with bed pressure mats to detect sleep patterns, restlessness, or agitation. When these technologies detect signals such as behavioral and activity changes, a digital phenotype can be established. Such setups are currently utilized in a variety of ways including discriminating between disease states[26], detecting agitation or apathy[27], unobtrusively monitoring response to therapeutics in care settings[28], and improving the selection of candidates for clinical research purposes[29].

Clinical research

The importance for understanding the landscape of ADRD-based DHTs is apparent when considering clinical research. Broadly, DHTs can improve trials by (a) reducing within-participant measurement noise [30], ultimately leading to improved statistical

DHTs for Alzheimer's disease and related

power, smaller trials[29], and faster paths to regulatory judgment of new therapies and (b) decentralizing assessments, enabling the participation of individuals located in more diverse geographical areas and therefore acquiring a more representative and diverse sample of the population under study[9]. (For explication of this approach, see Sliwinski, 2008)[31]. Although there is a recent example elsewhere in clinical research using a DHT as a primary clinical endpoint[32], this is not current practice in the ADRD space. However, the growing acceptance of DHTs as secondary endpoints in ADRD research[33, 34] is slowly moving the field towards this possibility[35, 36]. Studies employ DHTs for monitoring response to treatment in a variety of ways, such as using actigraphy to discern impacts of Mevidalen on activity and sleep within Lewy Body dementia cohorts[37, 38] or using smartwatches to detect suvorexant-induced changes in sleeping patterns for persons with Alzheimer's experiencing insomnia[39].

Digital neuropsychology

The dominance of technologies assessing memory (short term, long term, working), executive function, attention, processing speed, verbal fluency, and visuospatial processing document an increasingly digital shift within neuropsychological assessment. Clinicians see value in the opportunity to assess functional status in real world settings[40] even as they grapple with concerns around ecological validity[25, 41] due to variations in technology, computer literacy, environmental factors, and the presence or lack of supervision by a trained observer[41, 42]. While further research is needed to assuage these concerns, data continues to emerge illustrating that innovative digital assessment modalities can successfully discriminate between healthy controls and individuals in early stages of Alzheimer's disease[43]. Such DHTs provide clear advantages with regard to scalability and increasing access to patients

DHTs for Alzheimer's disease and related

for whom an in-person assessment may not be feasible[41], as well as the potential for real world and longitudinal evidence gathering[44] in populations where early detection is key. Many of the ambient technologies captured in this analysis were smartphone or tablet applications designed to analyze and interpret cognition or fine motor function to detect cognitive decline or discriminate between dementia states. Some examples include digital tasks testing aspects of cognition such as working memory, processing speed, or episodic memory[45]; executive function[46]; reaction time [47]; speech or text patterns[48, 49]; or pressure of a digital pen[50] on a device.

Wearables versus ambient sensors

Wearable sensors generally (32%), and smartwatches in particular (8%) were less represented in our landscape review than ambient technologies. Given their abundance and relative accessibility, wearable sensors can play an important role in the sensitive assessment of many ADRD-relevant measures, including mobility[51] (including but not limited to gait, life space pattern changes, and fall detection) and other biomarkers such as late-onset essential tremor[52] or heart rate variability[3]. However, the lower proportion of wearables to ambient technologies may be a reflection of the versatility and advantages of the latter for dementia populations. For example, ambient sensors may be more appropriate for populations where memory or awareness concerns might make adherence with wearables a challenge. The aforementioned smart home possibilities with cameras, pressure sensors, and/or smart speakers/smartphones that detect changes in behavioral patterns or vocal biomarkers offer a powerful modality for real world continuous data collection while posing minimal burden on patients or caregivers.

Diagnostic classifications

Our results encompass a wide spectrum of dementia diagnoses and severity classifications. However, we note the prevalence of Alzheimer's disease in our results compared to Frontotemporal dementias and Lewy Body dementia, as well as the prevalence of diagnoses like mild cognitive Impairment or general dementia as compared to results that specifically examined populations with moderate or advanced diagnoses. This suggests an opportunity for DHT developers and researchers to study additional uses and clinical validity within populations that are more narrowly defined within disease severity class, or in dementias other than Alzheimer's disease.

Digital Measurement Products Library: A living resource

The digital health technology landscape evolves rapidly. Technologies from this review with peer-reviewed evidence published 2020-present are collated into the Library of Digital Measurement Products, an open access resource hosted by DiMe[53] for the clinical, research, and developer communities. While our landscape analysis included evidence published between 2003-2023 featuring DHTs that are both commercial and experimental, the library is a living resource intended to assist researchers and clinicians who may be considering a current and specific use case. Thus, it describes DHTs that are commercially available on the market at the time of entry into the database, and is restricted to peer-reviewed evidence published from 2020-present. Evidence is tagged according to the study type by which it is reported in the published literature as verification, analytical validation, clinical validation, or usability[17]. Categorical fields are filterable so the end user can sort and view evidence according to a specific technology or technology type, therapeutic area or

DHTs for Alzheimer's disease and related

concept of interest, or by reported evidence type. This library aligns with the mission of the Digital Health Measurement Collaborative Community[13, 14] to share knowledge and resources to advance digital medicine and ultimately improve patient lives; we encourage the wider ADRD community to join our collective efforts to ensure diverse evidence-supported DHTs are represented in this important resource. A link to submit evidence for potential inclusion into the library is available to the public on DiMe's Library of Digital Measures Products web page[53]; beginning mid-2024, the library will be updated quarterly via review of community submissions, revisiting of the published literature, and removal of outdated evidence.

Limitations

While our results provide a broad overview of DHTs for ADRD assessment across 20 years of literature, we intentionally excluded brand-name identifiers from our search strings to avoid bias by disproportionately representing some market technologies over others. Additionally, we omitted search terms specific to Parkinson's disease dementia because it has differentiating features from other dementias, and therefore will be the focus of a similar exercise in future research. Due to this intentional limiting of some search terms, we do not claim the search results to be exhaustive. As we conducted this exercise to aggregate DHTs and their uses within ADRD, with a focus on extracting technologies rather than conducting a formal appraisal of the literature, we report these findings as a technology landscape analysis rather than a traditional systematic review.

Lastly, members of the DiMe working group made the authorship team aware of additional technologies which were not identified/discovered via the literature search.

DHTs for Alzheimer's disease and related

While this carries a risk of bias (primarily that some additional technologies were presumably overlooked due to being unknown to project partners), we considered that the benefits of greater inclusion outweighed this potential drawback. We reached out to solicit supporting evidence for these, but received evidence back for a small portion. Consequently, many of the technologies identified during partner review are not included in this analysis, as we lacked the associated evidence necessary to report on them.

Conclusion

DHTs show great promise for ADRD populations by enabling objective, continuous, and repeatable measurements of functioning and symptoms in a range of settings. Ambient, application-based, and wearable technologies offer vast real world and longitudinal evidence generation possibilities, as well as the opportunity to take traditional neuropsychological and neurocognitive assessment out of the clinic or laboratory and into homes and care settings. They offer additional information to facilitate clinical decision making, and provide opportunities for clinical research to identify earlier signals of disease onset, monitor disease trajectory, or detect response to therapeutic treatment at a time when demand is increasing for precision medicine that better identifies and targets appropriate candidates for care and intervention, particularly in the prodromal or earliest stages[54, 55]. These technologies continue to elucidate insights about domains such as cognitive function, sleep, mobility, language changes, and social and behavioral trends which will prove invaluable alongside traditional dementia research and management. This review confirms the multifaceted uses for and significant potential of DHTs as clinicians and researchers seek clarity and insights beyond the reach of traditional assessment modalities.

Supplementary Material: Search terms; technologies and citations identified

a. Search terms

Number	Theme/COIs	Terms
1	Performing activities of daily living	Activities of daily living; independent activities of daily living, Instrumental activities of daily living; Finances; scheduling; managing medicine; medication, dressing; eating/meals
2	Sleep health	Sleep onset latency; sleep quality; sleep waking; sleep duration; sleep staging; circadian; sleep disturbance; daytime sleepiness; sleep quality
3	Memory	Encoding; Episodic memory; learning; remembering; recollection
4	Language	Vocabulary; communication; fluency; speech; language; lexicon; lexical; linguistic; verbal fluency
5	Social connection/activities	time spent; distance; location; calendar; social; sms; social media; activities;
6	Oculomotor	Reaction time; eye movements; pupillometry
7	Cognition	Learning; skills; technological confidence; self-efficacy; digital literacy; attention; executive function; social cognition; app usage, cognitive function; cognitive dysfunction; cognitive impairment; cognitive decline; dementia
8	Life space mobility	Gait Function; walking; transitions; physical activity; driving; time spent; distance; location; navigation; Variability of activity; spatial awareness; balance
9	Essential bodily function	Eating; food; swallowing; dressing; showering; using the bathroom; continence
10	Emotions/behavioral issues	Depression; anxiety; emotion; emotional lability; anger; outbursts; emotional blunting, aggression; agitation; delirium; behavioral change; impulse control; impulsive; personality
11	Population of interest diagnostic status	Preclinical/MCI/Prodromal/Mild AD (Amnestic/non amnestic); Subjective Cognitive Decline; Subjective Cognitive Concerns; Cognitive Dysfunction; Mild Cognitive Impairment; Moderate AD; Severe AD; Vascular

DHTs for Alzheimer's disease and related

Dementia; FTD; Lewy body; General dementia;
Mixed-Domain Cognitive Impairment; Mixed AD/Vascular
Dementia

b. Technologies and evidence captured through literature search & partner review

Model	Manufacturer	Evidence Value
Actiwatch Spectrum	Philips	Au-Yeung, W. T. M., Miller, L., Beattie, Z., May, R., Cray, H. V., Kabelac, Z., ... & Vahia, I. V. (2022). Monitoring behaviors of patients with late-stage dementia using passive environmental sensing approaches: a case series. The American Journal of Geriatric Psychiatry, 30(1), 1-11.
Actiwatch Spectrum	Philips	Au-Yeung, W. T. M., Miller, L., Beattie, Z., Dodge, H. H., Reynolds, C., Vahia, I., & Kaye, J. (2020). Sensing a problem: Proof of concept for characterizing and predicting agitation. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12079.Chicago
AI Dialogue Agent	Experimental	Tang, F., Uchendu, I., Wang, F., Dodge, H. H., & Zhou, J. (2020). Scalable diagnostic screening of mild cognitive impairment using AI dialogue agent. Scientific reports, 10(1), 1-11.
Altoida ADPS	Altoida	Rai, L., Boyle, R., Brosnan, L., Rice, H., Farina, F., Tarnanas, I., & Whelan, R. (2020). Digital biomarkers based individualized prognosis for people at risk of dementia: the AltoidaML Multi-site External validation Study. In GeNeDis 2018: Computational Biology and Bioinformatics (pp. 157-171). Springer International Publishing.
Altoida DNS	Altoida	Harms, R. L., Ferrari, A., Meier, I. B., Martinkova, J., Santus, E., Marino, N., ... & Santuccione Chadha, A. (2022). Digital biomarkers and sex impacts in Alzheimer's disease management—potential utility for innovative 3P medicine approach. EPMA Journal, 13(2), 299-313.
Altoida DNS	Altoida	Meier, I. B., Buegler, M., Harms, R., Seixas, A., Çöltekin, A., & Tarnanas, I. (2021). Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: The Altoida large cohort study. NPJ Digital Medicine, 4(1), 101.
Altoida DNS	Altoida	Muurling, M., de Boer, C., Kozak, R., Religa, D., Koychev, I., Verheij, H., ... & Visser, P. J. (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's research & therapy, 13(1), 1-13.
Altoida DNS	Altoida	Seixas, A. A., Rajabli, F., Pericak-Vance, M. A., Jean-Louis, G., Harms, R. L., & Tarnanas, I. (2022). Associations of digital neuro-signatures with molecular and neuroimaging measures

DHTs for Alzheimer's disease and related

		of brain resilience: The altoida large cohort study. Frontiers in psychiatry, 13, 899080.
Altoida DNS	Altoida	Sood, M., Harms, R., Bügler, M., Tarnanas, I., Coello, N., & Fröhlich, H. (2021). Evaluating digital device technology in Alzheimer's disease via artificial intelligence. Alzheimer's & Dementia, 17, e053574.
Altoida DNS	Altoida	Tarnanas, I., Vlamos, P., & RADAR-AD Consortium. (2021). Can detection and prediction models for Alzheimer's Disease be applied to Prodromal Parkinson's Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures. Open Research Europe, 1(146), 146.
Altoida iADL task	Altoida	Tarnanas, I., Tsolaki, A., Wiederhold, M., Wiederhold, B., & Tsolaki, M. (2015). Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 1(4), 521-532.
Altoida Neuro Motor Index	Altoida	Buegler, M., Harms, R. L., Balasa, M., Meier, I. B., Exarchos, T., Rai, L., ... & Tarnanas, I. (2020). Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 12(1), e12073.
Ambulatory Research in Cognition (ARC) app	Cognitive Technology Research Laboratory (CTRLab), Washington University in St. Louis; Sage Bionetworks	Nicosia, J., Aschenbrenner, A. J., Balota, D. A., Sliwinski, M. J., Tahan, M., Adams, S., ... & Hassenstab, J. (2022). Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease. Journal of the International Neuropsychological Society, 1-13.
Ambulatory Research in Cognition (ARC) app	Cognitive Technology Research Laboratory (CTRLab), Washington University in St. Louis; Sage Bionetworks	Wilks, H., Aschenbrenner, A. J., Gordon, B. A., Balota, D. A., Fagan, A. M., Musiek, E., ... & Hassenstab, J. (2021). Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing. Journal of Clinical and Experimental Neuropsychology, 43(8), 825-837.
Amsterdam IADL Questionnaire	Alzheimer Center VU University Medical Center, Amsterdam, The Netherlands	Muurling, M., de Boer, C., Kozak, R., Religa, D., Koychev, I., Verheij, H., ... & Visser, P. J. (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's research & therapy, 13(1), 1-13.

DHTs for Alzheimer's disease and related

Automatic Speech Recognition algorithm	Experimental	Tóth, L., Hoffmann, I., Gosztolya, G., Vincze, V., Szatlóczki, G., Bánréti, Z., ... & Kálmán, J. (2018). A speech recognition-based solution for the automatic detection of mild cognitive impairment from spontaneous speech. Current Alzheimer Research, 15(2), 130-138.
AX3	Axivity	Corbi, A., & Burgos, D. (2022). Connection between sleeping patterns and cognitive deterioration in women with Alzheimer's disease. Sleep and Breathing, 1-11.
AX3	Axivity	Mc Ardle, R., Del Din, S., Donaghy, P., Galna, B., Thomas, A. J., & Rochester, L. (2021). The impact of environment on gait assessment: considerations from real-world gait analysis in dementia subtypes. Sensors, 21(3), 813.
AX3	Axivity	Mc Ardle, R., Del Din, S., Donaghy, P., Galna, B., Thomas, A., & Rochester, L. (2020). Factors that influence habitual activity in mild cognitive impairment and dementia. Gerontology, 66(2), 197-208.
AX3	Axivity	Mc Ardle, R., Del Din, S., Galna, B., Thomas, A., & Rochester, L. (2020). Differentiating dementia disease subtypes with gait analysis: feasibility of wearable sensors?. Gait & posture, 76, 372-376.
AX3	Axivity	Muurling, M., de Boer, C., Kozak, R., Religa, D., Koychev, I., Verheij, H., ... & Visser, P. J. (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's research & therapy, 13(1), 1-13.
AX3	Axivity	Wang, J., Battioui, C., McCarthy, A., Dang, X., Zhang, H., Man, A., ... & Biglan, K. (2022). Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia. Journal of Parkinson's Disease, (Preprint), 1-14.Chicago
Bedside AS (BAS) Task	Experimental	Hellmuth, J., Mirsky, J., Heuer, H. W., Matlin, A., Jafari, A., Garbutt, S., ... & Boxer, A. L. (2012). Multicenter validation of a bedside antisaccade task as a measure of executive function. Neurology, 78(23), 1824-1831.
Bittium Faros 180	Bittium	Godkin, F. E., Turner, E., Demnati, Y., Vert, A., Roberts, A., Swartz, R. H., ... & Van Ooteghem, K. (2021). Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease. Journal of neurology, 1-14.
Boston cognitive assessment (BOCA)	BellCurveAndMe	Vyshedskiy, A., Netson, R., Fridberg, E., Jagadeesan, P., Arnold, M., Barnett, S., ... & Gold, D. (2022). Boston cognitive assessment (BOCA)—a comprehensive self-administered smartphone-and computer-based at-home test for longitudinal tracking of cognitive performance. BMC neurology, 22(1), 1-12.
Boston Remote Assessment for Neurocognitive	Harvard Medical School / Mass General Brigham	Papp, K. V., Samaroo, A., Chou, H. C., Buckley, R., Schneider, O. R., Hsieh, S., ... & Amariglio, R. E. (2021). Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 13(1), e12243.

DHTs for Alzheimer's disease and related

Health (BRANCH)		
Brain Health Assessment (BHA)	Cogniciti	Paterson, T. S., Sivajohan, B., Gardner, S., Binns, M. A., Stokes, K. A., Freedman, M., ... & Troyer, A. K. (2022). Accuracy of a self-administered online cognitive assessment in detecting amnestic mild cognitive impairment. The Journals of Gerontology: Series B, 77(2), 341-350.
CANTAB	Cambridge Cognition	Baker, E., Dente, P., Backx, R., Lowther, M., Cotter, J., Cormack, F. K., & Barnett, J. (2020). Delivery of CANTAB assessments across diverse health systems: developing topics. Alzheimer's & Dementia, 16, e047550.
CANTAB	Cambridge Cognition	McWilliams, E. C., Barbey, F. M., Dyer, J. F., Islam, M. N., McGuinness, B., Murphy, B., ... & Buick, A. R. (2021). Feasibility of repeated assessment of cognitive function in older adults using a wireless, mobile, dry-EEG headset and tablet-based games. Frontiers in psychiatry, 12, 574482.
CANTAB	Cambridge Cognition	CC provided 140+ abstracts of clinical studies featuring CANTAB in Alzheimer's patient populations. Available upon request.
CANTAB	Cambridge Cognition	CC provided 72 abstracts featuring CANTAB in MCI patient populations. Available upon request.
CANTAB	Cambridge Cognition	CC provided abstracts featuring CANTAB in Lewy Body patient populations. Available upon request.
CANTAB	Cambridge Cognition	CC provided 12 abstracts featuring CANTAB in frontotemporal dementia populations. Available upon request.
CANTAB	Cambridge Cognition	CC provided 60+ abstracts of clinical studies featuring CANTAB in dementia populations. Available upon request.
Cascade Neural Network	Experimental	You, Z., Zeng, R., Lan, X., Ren, H., You, Z., Shi, X., ... & Hu, X. (2020). Alzheimer's disease classification with a cascade neural network. Frontiers in Public Health, 8, 584387.
Cognionics 2-channel EEG headband	CGX Systems	Casciola, A. A., Carlucci, S. K., Kent, B. A., Punch, A. M., Muszynski, M. A., Zhou, D., ... & Nygaard, H. B. (2021). A deep learning strategy for automatic sleep staging based on two-channel EEG headband data. Sensors, 21(10), 3316.
Cogstate Brief Battery	Cogstate	Maruff, P., Lim, Y. Y., Darby, D., Ellis, K. A., Pietrzak, R. H., Snyder, P. J., ... & Masters, C. L. (2013). Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC psychology, 1(1), 1-11.
Computerized Cognitive Composite (C3) battery	Cogstate	Jutten, R. J., Rentz, D. M., Fu, J. F., Mayblyum, D. V., Amariglio, R. E., Buckley, R. F., ... & Papp, K. V. (2022). Monthly at-home computerized cognitive testing to detect diminished practice effects in preclinical Alzheimer's disease. Frontiers in Aging Neuroscience, 13, 800126.
Cumulus Platform	Cumulus Neuroscience	510(k) Clearance K221963

DHTs for Alzheimer's disease and related

Cumulus Platform	Cumulus Neuroscience	McWilliams, E. C., Barbey, F. M., Dyer, J. F., Islam, M. N., McGuinness, B., Murphy, B., … & Buick, A. R. (2021). Feasibility of repeated assessment of cognitive function in older adults using a wireless, mobile, dry-EEG headset and tablet-based games. Frontiers in psychiatry, 12, 574482.
Cumulus Platform	Cumulus Neuroscience	UKCA Marking
Digital Clock and Recall (DCR)	Linus Health	Banks, R. E., Higgins, C., Bates, D., Gomes-Osman, J. R., Pascual-Leone, A., & Tobyne, S. E. (2022). Enhanced Machine Learning Classification of Cognitive Impairment with Multimodal Digital Biomarkers. Alzheimer's & Dementia, 18, e060485.
Digital Clock Drawing Test	Linus Health; Lahey Clinic and Massachusetts Institute of Technology	Binaco, R., Calzaretto, N., Epifano, J., McGuire, S., Umer, M., Emrani, S., … & Polikar, R. (2020). Machine learning analysis of digital clock drawing test performance for differential classification of mild cognitive impairment subtypes versus Alzheimer's disease. Journal of the International Neuropsychological Society, 26(7), 690-700.
Discrete Tension Indicator (DTI-2)	Philips	Melander, C. A., Kikhia, B., Olsson, M., Wälivaara, B. M., & Sävenstedt, S. (2019). The impact of using measurements of electrodermal activity in the assessment of problematic behaviour in dementia. Dementia and Geriatric Cognitive Disorders Extra, 8(3), 333-347.
Dreem 3 headband	Beacon	Wilson, S., Ardle, R. M., Tolley, C., & Slight, S. (2022). Usability and acceptability of wearable technology in the early detection of dementia. Alzheimer's & Dementia, 18, e059820.
DryBuddy	DryBuddy Enuresis Solutions	Rose, K. M., Lach, J., Perkhounkova, Y., Gong, J., Dandu, S. R., Dickerson, R., … & Stankovic, J. (2018). Use of body sensors to examine nocturnal agitation, sleep, and urinary incontinence in individuals with Alzheimer's disease. Journal of Gerontological Nursing, 44(8), 19-26.
DynaPort Hybrid	McRoberts	Van Lummel, R. C., Walgaard, S., Hobert, M. A., Maetzler, W., Van Dieën, J. H., Galindo-Garre, F., & Terwee, C. B. (2016). Intra-rater, inter-rater and test-retest reliability of an instrumented timed up and go (iTUG) test in patients with Parkinson's disease. PloS one, 11(3), e0151881.
DynaPort Hybrid	McRoberts	Van Uem, J. M., Walgaard, S., Ainsworth, E., Hasmann, S. E., Heger, T., Nussbaum, S., … & Maetzler, W. (2016). Quantitative timed-up-and-go parameters in relation to cognitive parameters and health-related quality of life in mild-to-moderate Parkinson's disease. PloS one, 11(4), e0151997.
Dynaport MoveMonitor	McRoberts	Schootemeijer, S., Weijer, R. H., Hoozemans, M. J., van Schooten, K. S., Delbaere, K., & Pijnappels, M. (2020). Association between daily-life gait quality characteristics and physiological fall risk in older people. Sensors, 20(19), 5580.

DHTs for Alzheimer's disease and related

DynaPort MT	McRoberts	Buchman, A. S., Dawe, R. J., Leurgans, S. E., Curran, T. A., Truty, T., Yu, L., … & Bennett, D. A. (2020). Different combinations of mobility metrics derived from a wearable sensor are associated with distinct health outcomes in older adults. The Journals of Gerontology: Series A, 75(6), 1176-1183.
Emerald	Emerald Innovations	Au-Yeung, W. T. M., Miller, L., Beattie, Z., May, R., Cray, H. V., Kabelac, Z., … & Vahia, I. V. (2022). Monitoring behaviors of patients with late-stage dementia using passive environmental sensing approaches: a case series. The American Journal of Geriatric Psychiatry, 30(1), 1-11.
Emerald	Emerald Innovations	Vahia, I. V., Kabelac, Z., Hsu, C. Y., Forester, B. P., Monette, P., May, R., … & Katabi, D. (2020). Radio signal sensing and signal processing to monitor behavioral symptoms in dementia: a case study. The American Journal of Geriatric Psychiatry, 28(8), 820-825.
Emfit Sleep Sensor	Emfit	Au-Yeung, W. T. M., Miller, L., Beattie, Z., Dodge, H. H., Reynolds, C., Vahia, I., & Kaye, J. (2020). Sensing a problem: Proof of concept for characterizing and predicting agitation. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12079.
Convolutional neural network using mobility data	Experimental	Bringas, S., Salomón, S., Duque, R., Lage, C., & Montaña, J. L. (2020). Alzheimer's disease stage identification using deep learning models. Journal of Biomedical Informatics, 109, 103514.
Convolutional neural network for gaze location estimation	Experimental	Jiang, Z., Seyedi, S., Haque, R. U., Pongos, A. L., Vickers, K. L., Manzanares, C. M., … & Clifford, G. D. (2022). Automated analysis of facial emotions in subjects with cognitive impairment. Plos one, 17(1), e0262527.
Convolutional neural network + LSTM for voice analysis	Experimental	Xue, C., Karjadi, C., Paschalidis, I. C., Au, R., & Kolachalama, V. B. (2021). Detection of dementia on voice recordings using deep learning: a Framingham Heart Study. Alzheimer's Research & Therapy, 13, 1-15.
EyeLink 1000 Plus	SR Research	Pavisic, I. M., Pertzov, Y., Nicholas, J. M., O'Connor, A., Lu, K., Yong, K. X., … & Crutch, S. J. (2021). Eye-tracking indices of impaired encoding of visual short-term memory in familial Alzheimer's disease. Scientific reports, 11(1), 8696.
EyeLink 1000 Plus	SR Research	Russell, L. L., Greaves, C. V., Convery, R. S., Nicholas, J., Warren, J. D., Kaski, D., & Rohrer, J. D. (2021). Novel instructionless eye tracking tasks identify emotion recognition deficits in frontotemporal dementia. Alzheimer's research & therapy, 13, 1-11.
FallSkip	Biomechanical Institute of Valencia, Valencia, Spain	Pedrero-Sánchez, J. F., Belda-Lois, J. M., Serra-Ano, P., Ingles, M., & Lopez-Pascual, J. (2022). Classification of healthy, Alzheimer and Parkinson populations with a multi-branch neural network. Biomedical Signal Processing and Control, 75, 103617.

DHTs for Alzheimer's disease and related

FallSkip	Biomechanical Institute of Valencia, Valencia, Spain	Serra-Añó, P., Pedrero-Sánchez, J. F., Hurtado-Abellán, J., Inglés, M., Espí-López, G. V., & López-Pascual, J. (2019). Mobility assessment in people with Alzheimer disease using smartphone sensors. Journal of NeuroEngineering and Rehabilitation, 16, 1-9.
Fitbit Charge 3	Fitbit	Muurling, M., de Boer, C., Kozak, R., Religa, D., Koychev, I., Verheij, H., ... & Visser, P. J. (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's research & therapy, 13(1), 1-13.
Fitbit Charge 4	Fitbit	Wilson, S., Ardle, R. M., Tolley, C., & Slight, S. (2022). Usability and acceptability of wearable technology in the early detection of dementia. Alzheimer's & Dementia, 18, e059820.
G2 Tracking Device	Azuga	Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., & Roe, C. M. (2021). GPS driving: a digital biomarker for preclinical Alzheimer disease. Alzheimer's Research & Therapy, 13(1), 1-9.
GAITRite	CIR Systems	Mc Ardle, R., Del Din, S., Galna, B., Thomas, A., & Rochester, L. (2020). Differentiating dementia disease subtypes with gait analysis: feasibility of wearable sensors?. Gait & posture, 76, 372-376.
GAITRite	CIR Systems	Tung, J. Y., Rose, R. V., Gammada, E., Lam, I., Roy, E. A., Black, S. E., & Poupart, P. (2014). Measuring life space in older adults with mild-to-moderate Alzheimer's disease using mobile phone GPS. Gerontology, 60(2), 154-162.
Garmin vívosmart HR	Garmin	Svetnik, V., Wang, T. C., Ceesay, P., Snyder, E., Ceren, O., Bliwise, D., ... & Herring, W. J. (2021). Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease. Journal of Sleep Research, 30(6), e13328.
GazePoint eye tracker	Gazepoint	Parra, M. A., Granada, J., & Fernández, G. (2022). Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), e12386.
GENEActiv	Activinsights	Godkin, F. E., Turner, E., Demnati, Y., Vert, A., Roberts, A., Swartz, R. H., ... & Van Ooteghem, K. (2021). Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease. Journal of neurology, 1-14.
GT3x+	ActiGraph	Ghosal, R., Varma, V. R., Volfson, D., Urbanek, J., Hausdorff, J. M., Watts, A., & Zipunnikov, V. (2022). Scalar on time-by-distribution regression and its application for modelling associations between daily-living physical activity and cognitive functions in Alzheimer's Disease. Scientific reports, 12(1), 11558.

DHTs for Alzheimer's disease and related

JiBuEn gait analysis system	Experimental	Huang, S., Zhou, X., Liu, Y., Luo, J., Lv, Z., Shang, P., ... & Xie, H. (2022). High Fall Risk Associated With Memory Deficit and Brain Lobes Atrophy Among Elderly With Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease. Frontiers in Neuroscience, 16, 793.
ki:e SB-C	ki elements	König, A., Linz, N., Baykara, E., Tröger, J., Ritchie, C., Saunders, S., ... & Hansson, O. (2023). Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol. The Journal of Prevention of Alzheimer's Disease, 1-8.
ki:e SB-C	ki elements	Linz, N., Mallick, E., Mina, M., Possemis, N., König, A., Huurne, D. B. T., ... & Tröger, J. (2022). validation of the ki: e SB-C a Novel Digital Speech Biomarker for Cognition in a Dutch Memory Clinic Population. [Poster presentation]. Alzheimer's & Dementia, 18, e061600.
ki:e SB-C	ki elements	Ruhmel, S., Troger, J., Linz, N., Herrmann, J., Quiceno, M., & Langel, K. (n.d.) Pre-Screening Prodromal AD Trial Populations over the Telephone Using a Speech Biomarker for Cognition — Preliminary Results from AUTONOMY Phase 2 AD Trial Recruitment. [Poster presentation]. Janssen Research & Development, LLC, United States. ki:elements, Saarbrücken, Germany. Janssen-Cilag, Spain.
ki:e SB-C	ki elements	S.G., M.H., H.P., M.W., E.M., J.T., N.J., N.L., A.K., S.R., H.P., S.L., J.H.,J.H., & C.W.R. [Manuscript in preparation]. Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: usability and acceptability results.
ki:e SB-C	ki elements	Schäfer, S., Mallick, E., Schwed, L., König, A., Zhao, J., Linz, N., ... & Tröger, J. (2022). Screening for Mild Cognitive Impairment Using a Machine Learning Classifier and the Remote Speech Biomarker for Cognition: Evidence from Two Clinically Relevant Cohorts. Journal of Alzheimer's Disease, (Preprint), 1-7.
ki:e SB-C	ki elements	Ter Huurne, D., Ramakers, I., Possemis, N., Banning, L., Gruters, A., Van Asbroeck, S., ... & de Vugt, M. (2023). The Accuracy of Speech and Linguistic Analysis in Early Diagnostics of Neurocognitive Disorders in a Memory Clinic Setting. Archives of Clinical Neuropsychology, acac105.
ki:e SB-C	ki elements	Tröger, J., Baykara, E., Zhao, J., Ter Huurne, D., Possemis, N., Mallick, E., ... & Ritchie, C. (2022). validation of the remote automated ki: e speech biomarker for cognition in mild cognitive impairment: Verification and validation following DiME V3 Framework. Digital biomarkers, 6(3), 107-116.
Kinect	Microsoft	König, A., Crispim-Junior, C. F., Covella, A. G. U., Bremond, F., Derreumaux, A., Bensadoun, G., ... & Robert, P. (2015). Ecological assessment of autonomy in instrumental activities of daily living in dementia patients by the means of an automatic video monitoring system. Frontiers in aging neuroscience, 7, 98.

DHTs for Alzheimer's disease and related

Kinect	Microsoft	Yang, Y. H., Lee, Y. H., Yen, C. W., Huang, L. C., Chang, Y. P., & Chien, C. F. (2022). Association between Cerebral Coordination Functions and Clinical Outcomes of Alzheimer's Dementia. Brain Sciences, 12(10), 1370.
Kinect	Microsoft	You, Z., Zeng, R., Lan, X., Ren, H., You, Z., Shi, X., ... & Hu, X. (2020). Alzheimer's disease classification with a cascade neural network. Frontiers in Public Health, 8, 584387.Chicago
Kinesis Balance	Linus Health Europe	Greene, B. R., Doheny, E. P., McManus, K., & Caulfield, B. (2022). Estimating balance, cognitive function, and falls risk using wearable sensors and the sit-to-stand test. Wearable technologies, 3, e9.
Kinesis Gait	Linus Health Europe	Ader, L. G. M., Greene, B. R., McManus, K., & Caulfield, B. (2021). Reliability of inertial sensor based spatiotemporal gait parameters for short walking bouts in community dwelling older adults. Gait & Posture, 85, 1-6.
Kinesis QTUG	Linus Health Europe	Greene, B. R., McManus, K., Redmond, S. J., Caulfield, B., & Quinn, C. C. (2019). Digital assessment of falls risk, frailty, and mobility impairment using wearable sensors. NPJ digital medicine, 2(1), 125.
LEGSys	BioSensics	Zhou, H., Lee, H., Lee, J., Schwenk, M., & Najafi, B. (2018). Motor planning error: toward measuring cognitive frailty in older adults using wearables. Sensors, 18(3), 926.
LEGSys	BioSensics	Zhou, H., Park, C., Shahbazi, M., York, M. K., Kunik, M. E., Naik, A. D., & Najafi, B. (2022). Digital biomarkers of cognitive frailty: The value of detailed gait assessment beyond gait speed. Gerontology, 68(2), 224-233.
LEGSys	BioSensics	Zhou, H., Sabbagh, M., Wyman, R., Liebsack, C., Kunik, M. E., & Najafi, B. (2017). Instrumented trail-making task to differentiate persons with no cognitive impairment, amnestic mild cognitive impairment, and Alzheimer disease: A proof of concept study. Gerontology, 63(2), 189-200.Chicago
M2C2: Mobile Monitoring of Cognitive Change	National Institute on Aging's Mobile Toolbox	Thompson, L. I., Harrington, K. D., Roque, N., Strenger, J., Correia, S., Jones, R. N., ... & Sliwinski, M. J. (2022). A highly feasible, reliable, and fully remote protocol for mobile app-based cognitive assessment in cognitively healthy older adults. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), e12283.
MetawearRG	MbientLab	Vahia, I. V., Kabelac, Z., Hsu, C. Y., Forester, B. P., Monette, P., May, R., ... & Katabi, D. (2020). Radio signal sensing and signal processing to monitor behavioral symptoms in dementia: a case study. The American Journal of Geriatric Psychiatry, 28(8), 820-825.
Mezurio	Digital Phenotyping Laboratory, Oxford University Big Data Institute	Lancaster, C., Koychev, I., Blane, J., Chinner, A., Chatham, C., Taylor, K., & Hinds, C. (2020). Gallery Game: Smartphone-based assessment of long-term memory in adults at risk of Alzheimer's disease. Journal of clinical and experimental neuropsychology, 42(4), 329-343.

DHTs for Alzheimer's disease and related

Mezurio	Digital Phenotyping Laboratory, Oxford University Big Data Institute	Lancaster, C., Koychev, I., Blane, J., Chinner, A., Wolters, L., & Hinds, C. (2020). Evaluating the feasibility of frequent cognitive assessment using the Mezurio smartphone app: observational and interview study in adults with elevated dementia risk. JMIR mHealth and uHealth, 8(4), e16142.
Mezurio	Digital Phenotyping Laboratory, Oxford University Big Data Institute	Muurling, M., de Boer, C., Kozak, R., Religa, D., Koychev, I., Verheij, H., ... & Visser, P. J. (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's research & therapy, 13(1), 1-13.
Mezurio	Digital Phenotyping Laboratory, Oxford University Big Data Institute	Wilson, S., Ardle, R. M., Tolley, C., & Slight, S. (2022). Usability and acceptability of wearable technology in the early detection of dementia. Alzheimer's & Dementia, 18, e059820.
mindLAMP	Dr. John Torous; Division of Digital Psychiatry at BIDMC	Weizenbaum, E. L., Fulford, D., Torous, J., Pinsky, E., Kolachalama, V. B., & Cronin-Golomb, A. (2022). Smartphone-based neuropsychological assessment in Parkinson's disease: feasibility, validity, and contextually driven variability in cognition. Journal of the International Neuropsychological Society, 28(4), 401-413.
MindWave Mobile EEG	NeuroSky	Iliadou, P., Paliokas, I., Zygouris, S., Lazarou, E., Votis, K., Tzovaras, D., & Tsolaki, M. (2021). A comparison of traditional and serious game-based digital markers of cognition in older adults with mild cognitive impairment and healthy controls. Journal of Alzheimer's disease, 79(4), 1747-1759.
Miro Health Mobile Assessment Platform	MiroHealth	Sloane, K. L., Mefford, J. A., Zhao, Z., Xu, M., Zhou, G., Fabian, R., ... & Glenn, S. (2022). validation of a Mobile, Sensor-based Neurobehavioral Assessment With Digital Signal Processing and Machine-learning Analytics. Cognitive and Behavioral Neurology, 35(3), 169-178.
mobile Detection Test of Language impairments in Adult (DTLA)	Experimental	Plonka, A., Mouton, A., Macoir, J., Tran, T. M., Derremaux, A., Robert, P., ... & Gros, A. (2021). Primary progressive aphasia: Use of graphical markers for an early and differential diagnosis. Brain Sciences, 11(9), 1198.
Motionlogger Actigraphs	Ambulatory Monitoring	Ancoli-Israel, S., Gehrman, P., Martin, J. L., Shochat, T., Marler, M., Corey-Bloom, J., & Levi, L. (2003). Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behavioral sleep medicine, 1(1), 22-36.

DHTs for Alzheimer's disease and related

Motionlogger Actigraphs	Ambulatory Monitoring	Nagels, G., Engelborghs, S., Vloeberghs, E., Van Dam, D., Pickut, B. A., & De Deyn, P. P. (2006). Actigraphic measurement of agitated behaviour in dementia. International journal of geriatric psychiatry, 21(4), 388-393.
Motionlogger Actigraphs	Ambulatory Monitoring	Tranah, G. J., Blackwell, T., Stone, K. L., Ancoli-Israel, S., Paudel, M. L., Ensrud, K. E., ... & SOF Research Group. (2011). Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Annals of neurology, 70(5), 722-732.
move II Activity Sensor	movisens	Schaat, S., Koldrack, P., Yordanova, K., Kirste, T., & Teipel, S. (2020). Real-time detection of spatial disorientation in persons with mild cognitive impairment and dementia. Gerontology, 66(1), 85-94.
mSTS-MCI	Experimental	Park, J. H., Jung, M., Kim, J., Park, H. Y., Kim, J. R., & Park, J. H. (2018). Validity of a novel computerized screening test system for mild cognitive impairment. International psychogeriatrics, 30(10), 1455-1463.
NAIHA Neuro Cognitive Test (NNCT)	Experimental	Oliva, I., & Losa, J. (2022). validation of the Computerized Cognitive Assessment Test: NNCT. International Journal of Environmental Research and Public Health, 19(17), 10495.
Nemuri SCAN sensor	Paramount Bed	Fukuda, C., Higami, Y., Shigenobu, K., Kanemoto, H., & Yamakawa, M. (2022). Using a Non-Wearable Actigraphy in Nursing Care for Dementia With Lewy Bodies. American Journal of Alzheimer's Disease & Other Dementias®, 37, 15333175221082747.
Nemuri SCAN sensor	Paramount Bed	Higami, Y., Yamakawa, M., Shigenobu, K., Kamide, K., & Makimoto, K. (2019). High frequency of getting out of bed in patients with Alzheimer's disease monitored by non-wearable actigraphy. Geriatrics & Gerontology International, 19(2), 130-134.
neotiv	neotiv	Berron, D., Glanz, W., Billette, O. V., Grande, X., Güsten, J., Hempen, I., ... & DELCODE Consortium. (2021). A remote digital memory composite to detect cognitive impairment in memory clinic samples in unsupervised settings using mobile devices. medrxiv, 2021-11.
neotiv	neotiv	Berron, D., Ziegler, G., Vieweg, P., Billette, O., Güsten, J., Grande, X., ... & Düzel, E. (2022). Feasibility of digital memory assessments in an unsupervised and remote study setting. Frontiers in digital health, 4, 892997.
neotiv	neotiv	Öhman, F., Berron, D., Papp, K. V., Kern, S., Skoog, J., Hadarsson Bodin, T., ... & Schöll, M. (2022). Unsupervised mobile app-based cognitive testing in a

DHTs for Alzheimer's disease and related

		population-based study of older adults born 1944. Frontiers in Digital Health, 4, 227.
neotiv	neotiv	Regulatory certificate and available languages: see supplementary resources field
Neural Impairment Test Suite	Experimental	Lauraitis, A., Maskeliūnas, R., Damaševičius, R., & Krilavičius, T. (2020). A mobile application for smart computer-aided self-administered testing of cognition, speech, and motor impairment. Sensors, 20(11), 3236.
Neurovocalix	Cambridge Cognition	Kaula, A. J., Cormack, F. K., & Taptiklis, N. (2021). Feasibility of repeated administration of automated verbal-paired-associate memory in older adults. Alzheimer's & Dementia, 17, e057804.
NIHTB-CB iPad English version	NIH	Ma, Y., Carlsson, C. M., Wahoske, M. L., Blazel, H. M., Chappell, R. J., Johnson, S. C., ... & Gleason, C. E. (2021). Latent factor structure and measurement invariance of the NIH toolbox cognition battery in an Alzheimer's Disease research sample. Journal of the International Neuropsychological Society, 27(5), 412-425.
NYCE Ambient sensors	NYCE Sensors	Au-Yeung, W. T. M., Miller, L., Beattie, Z., Dodge, H. H., Reynolds, C., Vahia, I., & Kaye, J. (2020). Sensing a problem: Proof of concept for characterizing and predicting agitation. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12079.
Opal	APDM Wearable Technologies	Kamil, R. J., Bakar, D., Ehrenburg, M., Wei, E. X., Pletnikova, A., Xiao, G., ... & Agrawal, Y. (2021). Detection of wandering behaviors using a body-worn inertial sensor in patients with cognitive impairment: A feasibility study. Frontiers in Neurology, 12, 529661.Chicago
OptiTrack	OptiTrack	Zhang, J., Xiao, Y., Li, Z. M., Wei, N., Lin, L., & Li, K. (2022). Reach-to-grasp kinematics and kinetics with and without visual feedback in early-stage Alzheimer's disease. Journal of NeuroEngineering and Rehabilitation, 19(1), 1-15.
ORCATECH Technology Platform	OHSU ORegon Center for Aging and TECHnology	Akl, A., Snoek, J., & Mihailidis, A. (2014, August). Generalized linear models of home activity for automatic detection of mild cognitive impairment in older adults. In 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (pp. 680-683). IEEE.
ORCATECH Technology Platform	OHSU ORegon Center for Aging and TECHnology	Akl, A., Taati, B., & Mihailidis, A. (2015). Autonomous unobtrusive detection of mild cognitive impairment in older adults. IEEE transactions on biomedical engineering, 62(5), 1383-1394.
ORCATECH Technology Platform	OHSU ORegon Center for Aging and TECHnology	Au-Yeung, W. T. M., Miller, L., Beattie, Z., May, R., Cray, H. V., Kabelac, Z., ... & Vahia, I. V. (2022). Monitoring behaviors of patients with late-stage dementia using passive environmental sensing approaches: a case series. The American Journal of Geriatric Psychiatry, 30(1), 1-11.

DHTs for Alzheimer's disease and related

ORCATECH Technology Platform	OHSU ORegon Center for Aging and TECHnology	Au-Yeung, W. T. M., Miller, L., Beattie, Z., Dodge, H. H., Reynolds, C., Vahia, I., & Kaye, J. (2020). Sensing a problem: Proof of concept for characterizing and predicting agitation. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12079.
ORCATECH Technology Platform	OHSU ORegon Center for Aging and TECHnology	Khan, T., & Jacobs, P. G. (2020). Prediction of mild cognitive impairment using movement complexity. IEEE journal of biomedical and health informatics, 25(1), 227-236.
ORCATECH Technology Platform	OHSU ORegon Center for Aging and TECHnology	Wu, C. Y., Beattie, Z., Mattek, N., Sharma, N., Kaye, J., & Dodge, H. H. (2021). Reproducibility and replicability of high-frequency, in-home digital biomarkers in reducing sample sizes for clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 7(1), e12220.
PAMSys	BioSensics LLC	Freytag, J., Mishra, R. K., Street Jr, R. L., Catic, A., Dindo, L., Kiefer, L., ... & Naik, A. D. (2022). Using Wearable Sensors to Measure Goal Achievement in Older Veterans with Dementia. Sensors, 22(24), 9923.
Passive Infrared (PIR) Sensors	DomoSafety SA	Botros, A. A., Schuetz, N., Röcke, C., Weibel, R., Martin, M., Müri, R. M., & Nef, T. (2022). Eigenbehaviour as an Indicator of Cognitive Abilities. Sensors, 22(7), 2769.
Physilog	MindMaze	Kuan, Y. C., Huang, L. K., Wang, Y. H., Hu, C. J., Tseng, I. J., Chen, H. C., & Lin, L. F. (2021). Balance and gait performance in older adults with early-stage cognitive impairment. Eur. J. Phys. Rehabil. Med, 57, 560-567.
Praat	Paul Boersma, David Weenink at University of Amsterdam	del Carmen Pérez-Sánchez, M., González-Nosti, M., Cuetos, F., Martínez, C., & Álvarez-Cañizo, M. (2021). Reading fluency in Spanish patients with Alzheimer's disease. Current Alzheimer Research, 18(3), 243-255.
Praat	Paul Boersma, David Weenink at University of Amsterdam	López-de-Ipiña, K., Alonso, J. B., Travieso, C. M., Solé-Casals, J., Egiraun, H., Faundez-Zanuy, M., ... & de Lizardui, U. M. (2013). On the selection of non-invasive methods based on speech analysis oriented to automatic Alzheimer disease diagnosis. Sensors, 13(5), 6730-6745.
Praat	Paul Boersma, David Weenink at University of Amsterdam	Tóth, L., Hoffmann, I., Gosztolya, G., Vincze, V., Szatlóczki, G., Bánréti, Z., ... & Kálmán, J. (2018). A speech recognition-based solution for the automatic detection of mild cognitive impairment from spontaneous speech. Current Alzheimer Research, 15(2), 130-138.
Praat	Paul Boersma, David Weenink at University of Amsterdam	Vincze, V., Szatlóczki, G., Tóth, L., Gosztolya, G., Pákáski, M., Hoffmann, I., & Kálmán, J. (2021). Telltale silence: temporal speech parameters discriminate between prodromal dementia and mild Alzheimer's disease. Clinical Linguistics & Phonetics, 35(8), 727-742.
Pro Pod 5	Trackershop	Ghosh, A., Puthusseryppady, V., Chan, D., Mascolo, C., & Hornberger, M. (2022). Machine learning detects altered spatial navigation features in outdoor behaviour of Alzheimer's disease patients. Scientific Reports, 12(1), 3160.

DHTs for Alzheimer's disease and related

Qualisys ProReflex	Qualisys	Ansai, J. H., de Andrade, L. P., Rossi, P. G., Nakagawa, T. H., Vale, F. A. C., & Rebelatto, J. R. (2019). Differences in timed up and go subtasks between older people with mild cognitive impairment and mild Alzheimer's disease. Motor Control, 23(1), 1-12.
Qualisys Track Manager	Qualisys	Ansai, J. H., de Andrade, L. P., Rossi, P. G., Nakagawa, T. H., Vale, F. A. C., & Rebelatto, J. R. (2019). Differences in timed up and go subtasks between older people with mild cognitive impairment and mild Alzheimer's disease. Motor Control, 23(1), 1-12.
RADAR-base passive RMT app (pRMT)	The Hyve	https://github.com/RADAR-base-Analytics/appdatacategorizati on
RADAR-base passive RMT app (pRMT)	The Hyve	Muurling, M., de Boer, C., Kozak, R., Religa, D., Koychev, I., Verheij, H., … & Visser, P. J. (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's research & therapy, 13(1), 1-13.
Rey-Osterrieth Complex Figure Test (RCFT) digital	Experimental	Kim, K. W., Lee, S. Y., Choi, J., Chin, J., Lee, B. H., Na, D. L., & Choi, J. H. (2020). A comprehensive evaluation of the process of copying a complex figure in early-and late-onset Alzheimer disease: a quantitative analysis of digital pen data. Journal of Medical Internet Research, 22(8), e18136.
RSSI Indoor Localization System	Experimental	Masciadri, A., Comai, S., & Salice, F. (2019). Wellness assessment of Alzheimer's patients in an instrumented health-care facility. Sensors, 19(17), 3658.
SENS Innovation ApS	SENS	Peimankar, A., Winther, T. S., Ebrahimi, A., & Wiil, U. K. (2023). A Machine Learning Approach for Walking Classification in Elderly People with Gait Disorders. Sensors, 23(2), 679.
Sensor Platform for HEalthcare in a Residential Environment (SPHERE)	University of Bristol	Kumpik, D. P., Santos-Rodriguez, R., Selwood, J., Coulthard, E., Twomey, N., Craddock, I., & Ben-Shlomo, Y. (2022). The use of home-based conversations for detecting early dementia: Protocol for the CUBOId TV task. medRxiv, 2022-05.
SensRing	BioRobotics Institute of Scuola Superiore Sant'Anna	Rovini, E., Galperti, G., Manera, V., Mancioppi, G., Fiorini, L., Gros, A., … & Cavallo, F. (2021). A wearable ring-shaped inertial system to identify action planning impairments during reach-to-grasp sequences: a pilot study. Journal of NeuroEngineering and Rehabilitation, 18, 1-11.
Silmee W20	TDK Corporation	Kimura, N., Aso, Y., Yabuuchi, K., Ishibashi, M., Hori, D., Sasaki, Y., … & Matsubara, E. (2020). Association of modifiable lifestyle factors with cortical amyloid burden and cerebral glucose metabolism in older adults with mild cognitive impairment. JAMA Network Open, 3(6), e205719-e205719.
Smart 2-Min Mobile Alerting Method for Mild Cognitive Impairment	Experimental	Wang, Y., Chen, T., Wang, C., Ogihara, A., Ma, X., Huang, S., … & Li, K. (2023). A New Smart 2-Min Mobile Alerting Method for Mild Cognitive Impairment Due to Alzheimer's Disease in the Community. Brain Sciences, 13(2), 244.

DHTs for Alzheimer's disease and related

Smart Aging Serious Game (SASG)	Consorzio di Bioingegneria e Informatica Medica	Cabinio, M., Rossetto, F., Isernia, S., Saibene, F. L., Di Cesare, M., Borgnis, F., … & Baglio, F. (2020). The use of a virtual reality platform for the assessment of the memory decline and the hippocampal neural injury in subjects with mild cognitive impairment: The validity of smart aging serious game (SASG). Journal of clinical medicine, 9(5), 1355.
Smart Aging Serious Game (SASG)	Consorzio di Bioingegneria e Informatica Medica	Isernia, S., Cabinio, M., Di Tella, S., Pazzi, S., Vannetti, F., Gerli, F., … & Baglio, F. (2021). Diagnostic validity of the smart aging serious game: an innovative tool for digital phenotyping of mild neurocognitive disorder. Journal of Alzheimer's Disease, 83(4), 1789-1801.
Speech Pause Analysis	Experimental	Yunusova, Y., Graham, N. L., Shellikeri, S., Phuong, K., Kulkarni, M., Rochon, E., … & Green, J. R. (2016). Profiling speech and pausing in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). PloS one, 11(1), e0147573.
Storyteller: Automatic Story Recall Task (ASRT)	Novoic	Fristed, E., Skirrow, C., Meszaros, M., Lenain, R., Meepegama, U., Cappa, S., … & Weston, J. (2022). A remote speech-based AI system to screen for early Alzheimer's disease via smartphones. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), e12366.
Storyteller: Automatic Story Recall Task (ASRT)	Novoic	Fristed, E., Skirrow, C., Meszaros, M., Lenain, R., Meepegama, U., Papp, K. V., … & Weston, J. (2022). Leveraging speech and artificial intelligence to screen for early Alzheimer's disease and amyloid beta positivity. Brain Communications, 4(5), fcac231.
Storyteller: Automatic Story Recall Task (ASRT)	Novoic	Skirrow, C., Meszaros, M., Meepegama, U., Lenain, R., Papp, K. V., Weston, J., & Fristed, E. (2022). validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study. JMIR aging, 5(3), e37090.
Storyteller: Automatic Story Recall Task (ASRT)	Novoic	Weiner, M. W., Veitch, D. P., Miller, M. J., Aisen, P. S., Albala, B., Beckett, L. A., … & Alzheimer's Disease Neuroimaging Initiative. (2023). Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimer's & Dementia, 19(1), 307-317.
Stricker Learning Span (SLS)	Experimental	Stricker, N. H., Stricker, J. L., Karstens, A. J., Geske, J. R., Fields, J. A., Hassenstab, J., … & Mielke, M. M. (2022). A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), e12299.
TEMPO (technology-enabled medical precision observation) nodes	University of Virginia Engineering	Rose, K. M., Lach, J., Perkhounkova, Y., Gong, J., Dandu, S. R., Dickerson, R., … & Stankovic, J. (2018). Use of body sensors to examine nocturnal agitation, sleep, and urinary incontinence in individuals with Alzheimer's disease. Journal of Gerontological Nursing, 44(8), 19-26.

DHTs for Alzheimer's disease and related

Tobii eye tracker	Tobii	Bott, N., Madero, E. N., Glenn, J., Lange, A., Anderson, J., Newton, D., ... & Zola, S. (2018). Device-embedded cameras for eye tracking–based cognitive assessment: validation with paper-pencil and computerized cognitive composites. Journal of medical Internet research, 20(7), e11143.
Tobii eye tracker	Tobii	Li, N., Yang, X., Du, W., Ogihara, A., Zhou, S., Ma, X., ... & Li, K. (2022). Exploratory Research on Key Technology of Human-Computer Interactive 2.5-Minute Fast Digital Early Warning for Mild Cognitive Impairment. Computational Intelligence and Neuroscience, 2022.
Traffic Light for Dementia" (TLiDe)	Experimental	Kwon, S. J., Kim, H. S., Han, J. H., Bae, J. B., Han, J. W., & Kim, K. W. (2021). Reliability and Validity of Alzheimer's Disease Screening With a Semi-automated Smartphone Application Using Verbal Fluency. Frontiers in Neurology, 12, 684902.
VALMA (Voice, Activity, and Location Monitoring for Alzheimer's Disease)	Neural & Rehabilitation Lab, University of Waterloo	Tung, J. Y., Rose, R. V., Gammada, E., Lam, I., Roy, E. A., Black, S. E., & Poupart, P. (2014). Measuring life space in older adults with mild-to-moderate Alzheimer's disease using mobile phone GPS. Gerontology, 60(2), 154-162.
Vehicular Onboard Data System	University of Michigan Transportation Research Institute	Eby, D. W., Silverstein, N. M., Molnar, L. J., LeBlanc, D., & Adler, G. (2012). Driving behaviors in early stage dementia: A study using in-vehicle technology. Accident Analysis & Prevention, 49, 330-337.
Verily Study Watch	Verily	Chen, C., Kowahl, N. R., Rainaldi, E., Burq, M., Munsie, L. M., Battioui, C., ... & Kapur, R. (2023). Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia. Parkinsonism & Related Disorders, 109, 105355.
Versatile wireless EEG	Bitbrain	Perez-Valero, E., Lopez-Gordo, M. Á., Gutiérrez, C. M., Carrera-Muñoz, I., & Vílchez-Carrillo, R. M. (2022). A self-driven approach for multi-class discrimination in Alzheimer's disease based on wearable EEG. Computer Methods and Programs in Biomedicine, 220, 106841.
Vestibular Rotation Task	Experimental	Coughlan, G., Plumb, W., Zhukovsky, P., Aung, M. H., & Hornberger, M. (2023). Vestibular contribution to path integration deficits in 'at-genetic-risk' for Alzheimer's disease. Plos one, 18(1), e0278239.
Vicon Nexus 2.8	Vicon	Ali, N., Liu, J., Tian, H., Pan, W., Tang, Y., Zhong, Q., ... & Zhu, Y. (2022). A novel dual-task paradigm with story recall shows significant differences in the gait kinematics in older adults with cognitive impairment: A cross-sectional study. Frontiers in Aging Neuroscience, 14.
ViewMind	ViewMind	Parra, M. A., Granada, J., & Fernández, G. (2022). Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), e12386.

DHTs for Alzheimer's disease and related

Virtual Supermarket Test (VST)	Centre for Research and Technology Hellas/ Information Technologies Institute (CERTH/ITI) in collaboration with the Greek Association of Alzheimer's Disease and Related Disorders (GAADRD)	Iliadou, P., Paliokas, I., Zygouris, S., Lazarou, E., Votis, K., Tzovaras, D., & Tsolaki, M. (2021). A comparison of traditional and serious game-based digital markers of cognition in older adults with mild cognitive impairment and healthy controls. Journal of Alzheimer's disease, 79(4), 1747-1759.
Virtual Supermarket Test (VST)	Centre for Research and Technology Hellas/ Information Technologies Institute (CERTH/ITI) in collaboration with the Greek Association of Alzheimer's Disease and Related Disorders (GAADRD)	Zygouris, S., Ntovas, K., Giakoumis, D., Votis, K., Doumpoulakis, S., Segkouli, S., ... & Tsolaki, M. (2017). A preliminary study on the feasibility of using a virtual reality cognitive training application for remote detection of mild cognitive impairment. Journal of Alzheimer's Disease, 56(2), 619-627.
VisMET (mobile)	Experimental	Haque, R. U., Pongos, A. L., Manzanares, C. M., Lah, J. J., Levey, A. I., & Clifford, G. D. (2020). Deep convolutional neural networks and transfer learning for measuring cognitive impairment using eye-tracking in a distributed tablet-based environment. IEEE Transactions on Biomedical Engineering, 68(1), 11-18.
W180	Shenzhen Fitfaith Technology	Liu, Z., Zhang, L., Wu, J., Zheng, Z., Gao, J., Lin, Y., ... & Zhou, Y. (2022). Machine learning-based classification of circadian rhythm characteristics for mild cognitive impairment in the elderly. Frontiers in Public Health, 10, 1036886.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Balagopalan, A., Eyre, B., Robin, J., Rudzicz, F., & Novikova, J. (2021). Comparing pre-trained and feature-based models for prediction of Alzheimer's disease based on speech. Frontiers in aging neuroscience, 13, 635945.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Fraser, K. C., Meltzer, J. A., & Rudzicz, F. (2016). Linguistic features identify Alzheimer's disease in narrative speech. Journal of Alzheimer's Disease, 49(2), 407-422.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Fraser, K. C., Meltzer, J. A., Graham, N. L., Leonard, C., Hirst, G., Black, S. E., & Rochon, E. (2014). Automated classification of primary progressive aphasia subtypes from narrative speech transcripts. cortex, 55, 43-60.

DHTs for Alzheimer's disease and related

Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Fraser, K. C., Rudzicz, F., & Rochon, E. (2013, August). Using text and acoustic features to diagnose progressive aphasia and its subtypes. In Interspeech (pp. 2177-2181).
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Kindellan, R., Sirotkin, S., Xu., M., Fidalgo, C., Simpson, W., & Robin, J. (2022, Nov 29-Dec 2). Accuracy of automated scoring of word recall assessments. [Poster presentation.] Clinical Trials for Alzheimer's Disease (CTAD), San Francisco, CA, USA. Winterlight Labs, Toronto, ON, Canada.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Kindellan, R., Xu, M., Ruan, J., Sirotkin, S., Robin, S. (2022). Analytical validation of automatic speech recognition tools used for voice biomarker development. [Poster presentation.] ISCTM Autumn Conference, 2022. Winterlight Labs, Toronto, ON, Canada.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Robin, J., Xu, M., Detke, M., & Simpson, W. (2022, Nov 29 - Dec 2). validation of an objective, speech-based object content score for measuring disease progression in AD. [Poster presentation.] Winterlight Labs, Toronto, ON, Canada. Detke Biopharma Consulting, Carmel, IN, USA. Department of Psychiatry and Behavioural Neuroscience. McMaster University, Hamilton, ON, Canada,
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Robin, J., Xu, M., Kaufman, L. D., & Simpson, W. (2021). Using digital speech assessments to detect early signs of cognitive impairment. Frontiers in digital health, 3, 749758.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Sorinas, J., Robin, J., Simpson, W., Curcic, J., & Hannesdottir, K. (2023). Speech phenotypes in cognitively healthy participants at risk of developing Alzheimer's disease. [Poster presentation.] Novartis Institutes for Biomedical Research, Basel, Switzerland. Winterlight Labs, Inc. Toronto, Canada. McMaster University, Hamilton, Canada. Novartis Institutes for Biomedical Research, Cambridge, MA, United States.
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Yancheva, M., Fraser, K. C., & Rudzicz, F. (2015, September). Using linguistic features longitudinally to predict clinical scores for Alzheimer's disease and related dementias. In Proceedings of SLPAT 2015: 6th Workshop on Speech and Language Processing for Assistive Technologies (pp. 134-139).
Winterlight Labs Speech Assessment	Winterlight Labs / Cambridge Cognition	Yeung, A., Iaboni, A., Rochon, E., Lavoie, M., Santiago, C., Yancheva, M., ... & Mostafa, F. (2021). Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer's dementia. Alzheimer's research & therapy, 13(1), 109.
Withings Go	Withings	McWilliams, E. C., Barbey, F. M., Dyer, J. F., Islam, M. N., McGuinness, B., Murphy, B., ... & Buick, A. R. (2021). Feasibility of repeated assessment of cognitive function in older adults using a wireless, mobile, dry-EEG headset and tablet-based games. Frontiers in psychiatry, 12, 574482.
Zeno Walkway	Protokinetics	Pieruccini-Faria, F., Sarquis-Adamson, Y., & Montero-Odasso, M. (2019). Mild cognitive impairment affects obstacle

DHTs for Alzheimer's disease and related

negotiation in older adults: results from "gait and brain study". Gerontology, 65(2), 164-173.

Abbreviations:

AD: Alzheimer's disease

ADRD: Alzheimer's disease and related dementias

DATAcc: Digital Health Measurement Collaborative Community

DHT: Digital health technology

EVIDENCE: EValuatIng connecteD sENsor teChnologiEs

V3: Verification, analytical validation, and clinical validation

Acknowledgments:

We appreciate the support of our collaborating partners and experts who comprise the DATAcc by DiMe ADRD Project working group and supported this manuscript: Abbvie; Altoida, Alzheimer's Drug Discovery Foundation, Aural Analytics, Biogen, BioSensics, Boston University, Cambridge Cognition, Cogniant Pte Ltd, Cognito Therapeutics, Cogstate, Cumulus Neuroscience, Eisai, Eli Lilly & Company, Gates Ventures, ki:elements, Koneksa, Linus Health, Luca Health, Medidata, Merck, Northwestern University, Oregon Health & Science University, Roche, Sage Bionetworks, VivoSense, Winterlight Labs.

Author Contributions:

All authors contributed to the conceptual development of this manuscript. All authors have approved the final submitted version and agree to be accountable for all aspects of the work presented here.

DHTs for Alzheimer's disease and related

Graphics:

Literature Screening Criteria	
Population	Exclude studies that do not capture data from human participants
	Include studies that reference a DHT used for assessment or diagnosis in Alzheimer's or related dementia populations
	Exclude studies limited to Parkinson's disease populations
Concept of interest	Include studies where a DHT focused on sleep health, memory, language, social function, oculomotor function, cognition, life space mobility, essential bodily functioning, and emotional or behavioral concerns
Application	Exclude studies where the featured DHT was: - being explicitly evaluated as a digital therapeutic or as an intervention - dependent on in-hospital or in-clinic administration and unlikely to be accessible in a real world setting, e.g., magnetic resonance or computed tomography imaging - an algorithm exclusively trained for and on aggregated imaging or electronic health record data. We did include any algorithms trained on data capable of being collected outside a laboratory setting through remote digital sensor technology
Evidence characteristics	Include studies with data reporting at least one of the following: - verification - analytical validation - clinical validation - use in clinical trial settings - usability or feasibility.
Time frame	Include studies published in the last 20 years

Table 1. Inclusion/exclusion criteria applied to identified papers in the landscape review.

DHTs for Alzheimer's disease and related

Population		Evidence Records (n=172)	Associated Technologies (n=106)
Dementia	Cognitive-Frailty	1	1
	Subjective Cognitive Decline	7	5
	Mild Cognitive Impairment (MCI)	67	52
	Prodromal Dementia	5	5
	Preclinical Dementia	21	16
	Mild Dementia	4	4
	Moderate Dementia	1	1
	Severe Dementia	1	1
	Dementia	55	44
	Vascular Dementia	3	3
Alzheimer's Disease	Prodromal Alzheimer's Disease	5	4
	Mild Cognitive Impairment (MCI), Alzheimer's Disease	27	21
	Mild Alzheimer's Disease	31	24
	Moderate Alzheimer's Disease	19	16
	Severe Alzheimer's Disease	9	9
	Alzheimer's Disease Not Otherwise Specified	53	42
Frontotemporal Dementia	Frontotemporal Dementia, behavioral variant	4	3
	Frontotemporal Dementia, primary progressive aphasia	6	4
	Frontotemporal Dementia	13	12
Lewy Body Dementia	Lewy Body Dementia	12	8
Parkinson's Disease	Prodromal Parkinson's Disease	1	1
	Parkinson's Disease	11	8

Table 2. Frequencies of population areas of focus in the library, with descriptors as reported in the literature. Many pieces of evidence reference multiple diagnostic classifications.

DHTs for Alzheimer's disease and related

Technology Type and Form Factor		Evidence Records (n-172)	Technologies (n=106)
Type	Ambient	117	65
	Wearables	45	34
	Combination ambient/wearable	10	7
Physical Form Factor*			
	Accessory such as ring or pendant	2	2
	Adhesive patch	6	4
	Camera	11	7
	Clothing	2	2
	Contactless	13	7
	Floor mat or plate	3	2
	Headset, helmet, or headband	8	6
	Mattress pad or sheet	3	2
	Microphone, handheld or fixed	7	1
	Other accessory**	5	5
	Ring	1	1
	Smartphone or tablet	78	44
	Strap or brace	27	20
	Watch	9	8

* not mutually exclusive **digitized pen, wearable pendant

Table 3. Prevalent technology types and form factors represented in the ADRD DHT library. Ambient includes environmental and software or application-based technologies.

DHTs for Alzheimer's disease and related

Health Concepts Being Assessed		Evidence Records (n=172)	Technologies (n=106)
Broad	Activities of daily living	11	10
	Mental health	8	6
	Neurocognitive	87	46
	Neurological or sensory	6	5
	Physical activity	72	51
	Sleep	20	16
		Evidence Records	Technologies
Specific, in order of frequency	Memory, general	45	28
	Life space mobility (physical functioning)	43	31
	Speech pattern or characteristics	36	14
	Gait	27	16
	Executive function	24	18
	Attention	17	9
	Language (production)	17	12
	Sleep duration or continuity	16	13
	Processing speed	15	10
	Working memory	15	9
	Fine motor function	14	7
	Visuospatial processing	14	9
	Energy expenditure	12	9
	Joint or head kinematics	10	9
	Gaze or visual movement	8	6
	Brain activity	6	5
	Performing activities of daily living	6	6
	Agitation	4	3
	Balance	4	3
	Sleep staging	4	4

Table 4. **Prevalent concepts of interest in the ADRD DHT library.** These are not mutually exclusive. These figures represent frequency in library evidence along with the number of corresponding technologies as of October 2023.

DHTs for Alzheimer's disease and related

References

1. Perry B, Herrington W, Goldsack JC, et al (2018) Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review. Digit Biomark 2:11–30

2. Abernethy A, Adams L, Barrett M, et al (2022) The Promise of Digital Health: Then, Now, and the Future. NAM Perspect. https://doi.org/10.31478/202206e

3. Kourtis LC, Regele OB, Wright JM, Jones GB (2019) Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity. NPJ Digit Med. https://doi.org/10.1038/s41746-019-0084-2

4. van Dyck CH, Swanson CJ, Aisen P, et al (2023) Lecanemab in Early Alzheimer's Disease. N Engl J Med 388:9–21

5. Watts KE, Storr NJ, Barr PG, Rajkumar AP (2023) Systematic review of pharmacological interventions for people with Lewy body dementia. Aging Ment Health 27:203–216

6. Trieu C, Gossink F, Stek ML, Scheltens P, Pijnenburg YAL, Dols A (2020) Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. Cogn Behav Neurol 33:1–15

7. Vaz M, Silva V, Monteiro C, Silvestre S (2022) Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. Clin Interv Aging 17:797–810

8. Manta C, Patrick-Lake B, Goldsack JC (2020) Digital Measures That Matter to Patients: A Framework to Guide the Selection and Development of Digital Measures of Health. Digit Biomark 4:69–77

9. (2023) Improving and Increasing Diversity, Equity, and Inclusion in Digitized Clinical Trial Design and Implementation. In: Digital Medicine Society. https://dimesociety.org/access-resources/diversity-equity-inclusion/. Accessed 1 Oct 2023

10. (2023) Digital Measures: Alzheimer's Disease and Related Dementias. In: Digital Medicine Society: DATAcc by DiMe. https://datacc.dimesociety.org/digital-measures-adrd/. Accessed 15 Feb 2024

11. Li X, Feng X, Sun X, Hou N, Han F, Liu Y (2022) Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019. Front Aging Neurosci 14:937486

12. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q (2022) The Humanistic and Economic Burden of Alzheimer's Disease. Neurol Ther 11:525–551

13. Digital Medicine Society DATAcc by the Digital Medicine Society (DiMe).

https://datacc.dimesociety.org/. Accessed 31 Jan 2024

14. Center for Devices, Radiological Health (2024) Collaborative Communities: Addressing Health Care Challenges Together. In: U.S. Food and Drug Administration. https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative -communities-addressing-health-care-challenges-together. Accessed 15 Feb 2024

15. Curcic J, Vallejo V, Sorinas J, et al (2022) Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study. JMIR Res Protoc 11:e35442

16. Muurling M, Hinds C, Wu Y, et al (2022) User experience and compliance rates of remote monitoring technologies in Alzheimer's disease: Preliminary results of the RADAR-AD study. Alzheimers Dement. https://doi.org/10.1002/alz.064507

17. Goldsack JC, Coravos A, Bakker JP, et al (2020) Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digit Med 3:55

18. DiBenedetti DB, Slota C, Wronski SL, et al (2020) Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther 12:90

19. Hauber B, Paulsen R, Callahan L, et al (2020) Quantifying what matters most to patients and care partners in Alzheimer's disease. Poster presented at

20. Corporation for Digital Scholarship Zotero.

21. Olaye IM, Belovsky MP, Bataille L, et al (2022) Recommendations for Defining and Reporting Adherence Measured by Biometric Monitoring Technologies: Systematic Review. J Med Internet Res 24:e33537

22. Sharma Y, Djambazova KV, Marquez CD, Lyden K, Goldsack JC, Bakker JP (2023) A systematic review assessing the state of analytical validation for connected, mobile, sensor-based digital health technologies. bioRxiv. https://doi.org/10.1101/2023.05.22.23290371

23. Qualtrics (2015) Qualtrics XM - Experience Management Software.

24. Torous J, Kiang MV, Lorme J, Onnela J-P (2016) New Tools for New Research in Psychiatry: A Scalable and Customizable Platform to Empower Data Driven Smartphone Research. JMIR Ment Health 3:e16

25. Hackett K, Giovannetti T (2022) Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools. JMIR Aging 5:e38130

26. Akl A, Taati B, Mihailidis A (2015) Autonomous unobtrusive detection of mild cognitive impairment in older adults. IEEE Trans Biomed Eng 62:1383–1394

27. Au-Yeung W-TM, Miller L, Beattie Z, May R, Cray HV, Kabelac Z, Katabi D, Kaye J, Vahia IV (2022) Monitoring Behaviors of Patients With Late-Stage Dementia Using

Passive Environmental Sensing Approaches: A Case Series. Am J Geriatr Psychiatry 30:1–11

28. Thomas NWD, Beattie Z, Marcoe J, Wright K, Sharma N, Mattek N, Dodge H, Wild K, Kaye J (2020) An Ecologically Valid, Longitudinal, and Unbiased Assessment of Treatment Efficacy in Alzheimer Disease (the EVALUATE-AD Trial): Proof-of-Concept Study. JMIR Res Protoc 9:e17603

29. Wu C-Y, Beattie Z, Mattek N, Sharma N, Kaye J, Dodge HH (2021) Reproducibility and replicability of high-frequency, in-home digital biomarkers in reducing sample sizes for clinical trials. Alzheimers Dement 7:e12220

30. Öhman F, Hassenstab J, Berron D, Schöll M, Papp KV (2021) Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimers Dement 13:e12217

31. Sliwinski MJ (2008) Measurement-burst designs for social health research. Soc Personal Psychol Compass 2:245–261

32. (2023) Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease. In: Bellerophon Therapeutics, Inc. https://investors.bellerophon.com/news-releases/news-release-details/belleropho n-announces-top-line-data-phase-3-rebuild-clinical. Accessed 5 Jun 2023

33. CLAIRE E. O'HANLON, CARRIE M. FARMER, JAMIE RYAN, NATALIE ERNECOFF (2023) Clinical Outcome Assessments and Digital Health Technologies Supporting Clinical Trial Endpoints in Early Parkinson's Disease: Roundtable Proceedings and Roadmap for Research. RAND

34. Perry B, Kehoe L, Swezey T, Le Masne Q, Goldhahn J, Staley A, Corneli A (2023) How Much Evidence Is Enough? Research Sponsor Experiences Seeking Regulatory Acceptance of Digital Health Technology-Derived Endpoints. Digit Biomark 7:45–53

35. Masanneck L, Gieseler P, Gordon WJ, Meuth SG, Stern AD (2023) Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials. NPJ Digit Med 6:23

36. Brem A-K, Kuruppu S, de Boer C, et al (2023) Digital endpoints in clinical trials of Alzheimer's disease and other neurodegenerative diseases: challenges and opportunities. Front Neurol 14:1210974

37. Wang J, Battioui C, McCarthy A, et al (2022) Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia. J Parkinsons Dis 12:1991–2004

38. Chen C, Kowahl NR, Rainaldi E, Burq M, Munsie LM, Battioui C, Wang J, Biglan K, Marks WJ Jr, Kapur R (2023) Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia. Parkinsonism Relat Disord 109:105355

39. Svetnik V, Wang T-C, Ceesay P, et al (2021) Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease. J Sleep Res 30:e13328

40. Parsons T, Duffield T (2020) Paradigm Shift Toward Digital Neuropsychology and High-Dimensional Neuropsychological Assessments: Review. J Med Internet Res 22:e23777

41. Van Patten R (2021) Introduction to the Special Issue - Neuropsychology from a distance: Psychometric properties and clinical utility of remote neurocognitive tests. J Clin Exp Neuropsychol 43:767–773

42. Lunardini F, Luperto M, Romeo M, et al (2020) Supervised Digital Neuropsychological Tests for Cognitive Decline in Older Adults: Usability and Clinical Validity Study. JMIR Mhealth Uhealth 8:e17963

43. Muurling M, de Boer C, Vairavan S, et al (2023) Augmented reality versus standard tests to assess cognition and function in early Alzheimer's disease. NPJ Digit Med 6:234

44. Hampshire A, Ballard C, Williams G (2020) Computerized neuropsychological tests undertaken on digital platforms are cost effective, achieve high engagement, distinguish and are highly sensitive to longitudinal change: Data from the PROTECT and GBIT studies. Alzheimers Dement. https://doi.org/10.1002/alz.041122

45. Thompson LI, Harrington KD, Roque N, Strenger J, Correia S, Jones RN, Salloway S, Sliwinski MJ (2022) A highly feasible, reliable, and fully remote protocol for mobile app-based cognitive assessment in cognitively healthy older adults. Alzheimers Dement 14:e12283

46. Tarnanas I, Tsolaki A, Wiederhold M, Wiederhold B, Tsolaki M (2015) Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps? Alzheimers Dement 1:521–532

47. Seixas AA, Rajabli F, Pericak-Vance MA, Jean-Louis G, Harms RL, Tarnanas I (2022) Associations of digital neuro-signatures with molecular and neuroimaging measures of brain resilience: The altoida large cohort study. Front Psychiatry 13:899080

48. Yeung A, Iaboni A, Rochon E, et al (2021) Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer's dementia. Alzheimers Res Ther 13:109

49. Fraser KC, Rudzicz F, Rochon E (2013) Using text and acoustic features to diagnose progressive aphasia and its subtypes. Interspeech 2013. https://doi.org/10.21437/interspeech.2013-514

50. Kim KW, Lee SY, Choi J, Chin J, Lee BH, Na DL, Choi JH (2020) A Comprehensive Evaluation of the Process of Copying a Complex Figure in Early- and Late-Onset

Alzheimer Disease: A Quantitative Analysis of Digital Pen Data. J Med Internet Res 22:e18136

51. Cullen A, Mazhar MKA, Smith MD, Lithander FE, Ó Breasail M, Henderson EJ (2022) Wearable and Portable GPS Solutions for Monitoring Mobility in Dementia: A Systematic Review. Sensors . https://doi.org/10.3390/s22093336

52. Wang X, St George RJ, Bai Q, Tran S, Alty J (2022) New horizons in late-onset essential tremor: a pre-cognitive biomarker of dementia? Age Ageing. https://doi.org/10.1093/ageing/afac135

53. (2024) Library of Digital Measurement Products. In: DATAcc by DiMe. https://datacc.dimesociety.org/digital-measurement-library/. Accessed 27 Feb 2024

54. Forloni G (2020) Alzheimer's disease: from basic science to precision medicine approach. BMJ Neurol Open 2:e000079

55. Lukiw WJ, Vergallo A, Lista S, Hampel H, Zhao Y (2020) Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. J Pers Med. https://doi.org/10.3390/jpm10030138